Betaglue® Therapeutics

Description

Betaglue® Therapeutics develops localized radiotherapeutic platforms delivering radiation directly into solid tumors, producing precision intratumoral treatments such as YntraDose for hard-to-treat cancers and clinical research sites.

Betaglue® Therapeutics is located in the Milan ecosystem.

Related

• ActitheraActithera develops precisely targeted radioligand therapies by linking radioactive isotopes to designed molecules, producing…
• ElektaElekta develops radiotherapy, brachytherapy and imaging systems for precision radiation medicine used by hospitals and cancer centres to…
• CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
• NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
• OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
• CollimateHealthCollimateHealth develops microbeam radiation systems that deliver arrays of extremely narrow radiation beams to treat tumors while sparing…
• Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
• ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
• NeoPhoreNeoPhore develops small-molecule cancer therapeutics that briefly inhibit DNA mismatch repair, shifting MMR-proficient tumors toward an…